United Therapeutics Corporation (NASDAQ:UTHR) Files An 8-K Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure.

On April3, 2017, United Therapeutics Corporation issued the press
release attached hereto as Exhibit99.1 and incorporated herein by
reference.

The information contained in Item 7.01 to this Current Report on
Form8-K, and Exhibits 99.1 attached hereto, shall not be deemed
to be filed for the purposes of Section18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to
liability under that section, nor shall it be deemed incorporated
by reference into any filing under the Securities Act of 1933, as
amended, except as shall be expressly set forth by specific
reference in such filing.

Item 9.01. Exhibits

(d) Exhibits

About United Therapeutics Corporation (NASDAQ:UTHR)

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb). Its Prostacyclin Analogues lead product is Remodulin (treprostinil) Injection. It also includes Tyvaso (treprostinil) Inhalation Solution and Orenitram (treprostinil) Extended-Release Tablets. Its subsidiary is developing another oral prostacyclin analogue for the treatment of pulmonary arterial hypertension (PAH) called esuberaprost. Its PDE-5 inhibitor is Adcirca (tadalafil) tablets are indicated for the treatment of PAH. Its Unituxin (dinutuximab) Injection in combination with granulocyte-macrophage colony-stimulating factor, interleukin-2 and 13-cis-retinoic acid is indicated for the treatment of pediatric patients with neuroblastoma.

United Therapeutics Corporation (NASDAQ:UTHR) Recent Trading Information

United Therapeutics Corporation (NASDAQ:UTHR) closed its last trading session down -0.97 at 135.38 with 978,554 shares trading hands.